$CRDF News

Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

HC Wainwright & Co. Upgrades Cardiff Oncology to Buy, Announces $9 Price Target

Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

Cardiff Oncology, Inc. (CRDF) Presents at 8th Annual RAS-Targeted Drug Development Summit - Slideshow

Cardiff Oncology to Participate in September 2026 Conferences

CRDF: Second Quarter Earnings

William Blair Downgrades Cardiff Oncology to Market Perform

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Cardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate

Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital

Cardiff Oncology Announces $10 Million Registered Direct Offering

Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?

CRDF: Phase II Update; Survival Advantage Extended

Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer - Slideshow

Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript

Craig-Hallum Downgrades Cardiff Oncology to Hold, Lowers Price Target to $2

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

Cardiff Oncology Announces Presentation Of Phase 2 Trial Data For RAS-Mutated mCRC Treatment Onvansertib At ASCO Annual Meeting On June 2

Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference

TD Cowen Downgrades Cardiff Oncology to Hold